We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$8.82B
AUM Growth
+$974M
Cap. Flow
+$109M
Cap. Flow %
1.24%
Top 10 Hldgs %
37.09%
Holding
149
New
20
Increased
26
Reduced
29
Closed
13

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$111M
2
AGN.PRA
Allergan plc
AGN.PRA
+$73.1M
3
MRK icon
Merck
MRK
+$69.9M
4
AET
Aetna Inc
AET
+$63.6M
5
VTRS icon
Viatris
VTRS
+$52.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$148M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.3M
3
AGN
Allergan plc
AGN
+$68.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$67.6M
5
SHPG
Shire pic
SHPG
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.67%
2 Miscellaneous 2.15%
3 Financials 2.15%
4 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
126
Vanda Pharmaceuticals
VNDA
$304M
$703K 0.01%
+50,200
New +$715K
ALIM
127
DELISTED
Alimera Sciences
ALIM
$350K ﹤0.01%
16,667
– –
XTNT icon
128
Xtant Medical Holdings
XTNT
$45.2M
$296K ﹤0.01%
39,620
– –
XYLO
129
DELISTED
Xylo Technologies
XYLO
$185K ﹤0.01%
375
– –
ABT icon
130
Abbott
ABT
$176B
– –
-245,400
Closed -$9.43M
AMED
131
DELISTED
Amedisys
AMED
– –
-71,500
Closed -$3.05M
HUM icon
132
CALL
Humana
HUM
$47.6B
– –
-100,000
Closed -$20.4M
LLY icon
133
CALL
Eli Lilly
LLY
$1.02T
– –
-150,000
Closed -$11M
MOH icon
134
Molina Healthcare
MOH
$10.9B
– –
-496,200
Closed -$26.9M
PTCT icon
135
PTC Therapeutics
PTCT
$5.45B
– –
-204,400
Closed -$2.23M
RARE icon
136
Ultragenyx Pharmaceutical
RARE
$1.29B
– –
-169,300
Closed -$11.9M
RCKT icon
137
Rocket Pharmaceuticals
RCKT
$359M
– –
-462,325
Closed -$11.3M
SGMO
138
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-707,400
Closed -$2.16M
VNDA icon
139
CALL
Vanda Pharmaceuticals
VNDA
$304M
– –
-750,000
Closed -$12M
PTLA
140
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-551,500
Closed -$12.4M
FWP
141
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-114,000
Closed -$12M
ARLZ
142
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
– –
-68,143
Closed -$301K
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2017 Portfolio in Review

As of Q1 2017, OrbiMed held 149 positions worth $8.82B, up 12% from $7.85B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q1 2017 filing shows 20 new, 26 increased, 29 reduced and 13 closed positions. Its largest new stake was Centene: 3,311,400 shares worth $118M. The largest sale was Amgen, an estimated $148M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

  • OrbiMed's largest Q1 2017 buy was Centene: 3,311,400 shares worth $118M.
  • OrbiMed added most to Merck in Q1 2017, an estimated $69.9M increase.
  • OrbiMed's biggest Q1 2017 reduction was Amgen, cutting an estimated $148M.
  • OrbiMed fully exited Molina Healthcare in Q1 2017, selling an estimated $26.9M.
  • OrbiMed's ten largest holdings make up 37% of its $8.82B portfolio in Q1 2017.
  • OrbiMed opened 20 new positions and closed 13 in Q1 2017.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $8.82B.

Based on OrbiMed's 13F filing for Q1 2017, filed 15 May 2017.